OraSure Technologies Inc., Bethlehem, Pennsylvania, was awarded a $109,000,000 firm-fixed-price contract for the increased domestic manufacturing capability of rapid antigen self-tests for home care testing. This contract provides for the retrofit of a production facility and a new additional facility with machinery to increase domestic COVID-19 rapid test production capacity. Work will be performed in Bethlehem, Pennsylvania, and is expected to be completed by March 31, 2024. This award is the result of a COVID-19 Joint Acquisition Task Force Commercial Solution Opening. Fiscal 2021 American Rescue Plan Act, Department of Health and Human Services other funds in the amount of $109,000,000 are being obligated at the time of the award. There are known congressional interest in this action. Air Force Life Cycle Management Center, Hanscom Air Force Base, Massachusetts, is the contracting activity (FA8730-21-S-C001). (Awarded Sept. 30, 2021)

When it comes to diagnostic tests, OraSure is certain it can deliver results. The oral specimen kits and other diagnostic tests developed by OraSure Technologies are designed to detect drug use and certain infectious diseases, namely HIV and hepatitis C. Its OraSure products use oral specimens rather than traditional blood or urine-based methods to test for HIV. The Intercept line uses oral samples to test for marijuana, cocaine, opiates, PCP, and amphetamines. OraSure has also developed a rapid HIV blood diagnostic testing method, and it has entered the genetic testing market through its DNAG subsidiary. OraSure sells its products in the US (largest single market) and internationally to health care facilities and medical laboratories.   (www.dnb.com)